Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score

EULAR ^® 2019

Systemic Sclerosis-Associated Interstitial Lung Disease

Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Further Publications Rheumatology

Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of the SENSCIS trial

Arthritis Rheumatol

Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G, SENSCIS trial investigators.

doi: 10.1002/art.41576

RECOMMENDED

Systemic Sclerosis

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Ann Rheum Dis

Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators.

doi: 10.1136/annrheumdis-2020-217331

Systemic Sclerosis

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Rheumatology (Oxford)

Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM

doi: 10.1093/rheumatology/keaa547

Systemic Sclerosis

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

Arthritis Rheumatol.

Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V

doi: 10.1002/art.41512.

Further Publications Rheumatology

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Respirology

Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, Alfieri V, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Chua F, Maher TM, Abraham DJ, Ong V, Donovan J, Sestini P, Denton CP, Wells AU, Renzoni EA

doi: 10.1111/resp.13988

Systemic Sclerosis

Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity

Rheumatology (Oxford).

Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, Baron M, Canadian Scleroderma Research Group .

doi: 10.1093/rheumatology/kez299.

Systemic SclerosisFurther Publications Rheumatology

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Semin Arthritis Rheum

Roofeh D, Barratt SL, Wells AU, Kawano-Dourado L, Tashkin D, Strand V, Seibold J, Proudman S, Brown KK, Dellaripa PF, Doyle T, Leonard T, Matteson EL, Oddis CV, Solomon JJ, Sparks JA, Vassallo R, Maxwell L, Beaton D, Christensen R, Townsend W, Khanna D

doi: 10.1016/j.semarthrit.2021.08.001

Systemic Sclerosis

STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease

J Rheumatol

Khanna D, Tashkin DP, Wells AU, Seibold JR, Wax S, Vazquez-Mateo C, Fleuranceau-Morel P, Damian D, Denton CP

doi: 10.3899/jrheum.191365

Related content

Systemic Sclerosis-Associated Interstitial Lung Disease

Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of the SENSCIS trial

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease